ArticleCell discovery2022
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
Yingdan Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this papercites it